linjc16/ctgov huggingface dataset:
Cortisol and the Formation of Intrusive Memories

Study Overview
=================
Brief Summary
-----------------
Intrusive memories of traumatic events are core features of posttraumatic stress disorder (PTSD) but little is known about the neurobiological formation of intrusions. The aim of this study was to determine whether cortisol levels during an intrusion-inducing stressor influence subsequent intrusive memories.

Detailed Description
-----------------
The investigators conducted an experimental, double-blind, placebo-controlled study in 60 healthy women. Prior to watching an established trauma film paradigm that induces short lasting intrusions, participants received a single dose of either 10 mg hydrocortisone or placebo. The number of consecutive intrusions of the trauma film, the mean vividness of the intrusions and the mean degree of distress evoked by the intrusions were assessed during the following seven days. Salivary cortisol and alpha-amylase were collected at seven time points prior to, and after the trauma film.

Official Title
-----------------
Cortisol and the Formation of Intrusive Memories: An Experimental Approach With a Trauma Film Paradigm

Conditions
-----------------
Intrusive Memories

Intervention / Treatment
-----------------
* Behavioral: Stress Film
* Drug: Hydrocortisone
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy participants German on a native level Exclusion Criteria: former or present DSM IV Axis I disorders physical illnesses any medication intake (except oral contraceptive) history of sexual abuse or rape pregnancy or lactation period

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 34 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Hydrocortisone and Stress Film<br>Administration of 10mg hydrocortisone before the trauma film. | Behavioral: Stress Film<br>* Film scene with severe physical and sexual violence.<br>Drug: Hydrocortisone<br>* 10mg<br>|
| Experimental: Placebo and Stress Film<br>Administration of placebo before the trauma film. | Behavioral: Stress Film<br>* Film scene with severe physical and sexual violence.<br>Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of intrusive memories | Measured with an intrusion diary | seven consecutive days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vividness of intrusive memories | Measured with an intrusion diary | seven consecutive days | 
| Degree of distress of intrusive memories | Measured with an intrusion diary | seven consecutive days |
PHACE - Prospective Genetic Investigation

Study Overview
=================
Brief Summary
-----------------
Investigation for potential PHACE syndrome gene.

Detailed Description
-----------------
Subjects with PHACE syndrome diagnosis will undergo a brief physical examination with possible external photographs. Cheek swabs will be sent for genetic analysis. Subjects will be notified of the results.

Official Title
-----------------
PHACE - Prospective Genetic Investigation

Conditions
-----------------
PHACE Syndrome

Intervention / Treatment
-----------------
* Other: Diagnostic study only


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: PHACE syndrome diagnosis Must be willing to have an eye examination Must be willing to undergo genetic testing Exclusion Criteria: No PHACE syndrome diagnosis
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Diagnostic study only|Diagnostic study only|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Potential PHACE Gene Identification | Evaluation for potential PHACE gene | 3 years |
Preliminary Safety and Efficacy of the PDS-1.0 in Patients With Neovascular Age Related Macular Degeneration (AMD)

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the preliminary safety and efficacy of PDS 1.0 in patients with neovascular AMD.

Conditions
-----------------
Age-Related Macular Degeneration

Intervention / Treatment
-----------------
* Drug: PDS 1.0


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of CNV secondary to AMD confirmed by fluorescein angiography, not previously treated Retinal thickness due to edema of at least 300um in the study eye Best corrected visual acuity of 20/40 or worse in the study eye Best corrected visual acuity of 20/40 or better in the fellow eye Exclusion Criteria: Evidence of scarring CNV (e.g. geographic atrophy) in the study eye Fibrosis >75% of lesion area in the study eye

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Active<br>ranibizumab sustained delivery implant | Drug: PDS 1.0<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in retinal thickness measured by Optical Coherence Tomography |  | Monthly | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Best Corrected Visual Acuity |  | Monthly |
Retrospective Study on Epidemiology of Colorectal Lesions

Study Overview
=================
Brief Summary
-----------------
Retrospective analysis on colonoscopies in the endoscopy unit of the Lyell McEwin Hospital.

Detailed Description
-----------------
Colonoscopy reports will be manually searched by the investigator to evaluate epidemiology on colorectal lesions.

Official Title
-----------------
Retrospective Study on Epidemiology of Colorectal Lesions

Conditions
-----------------
ColoRectal Cancer, Colonic Polyp, Colonic Neoplasms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Colonoscopies performed in Lyell McEwin Hospital between 2010-2016 Exclusion Criteria: Sigmoidoscopies
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with colorectal lesions<br>Patients with a full colonoscopy that showed either a cancer or a polyp. | |
| Patients without colorectal lesions<br>Patients with a full colonoscopy that showed no polyps. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adenoma detection rate | Percentage of screening patients with at least one adenomatous lesion found - to be compared between Gastroenterologists and Surgeons and based on scheduling of the procedure | Day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SSA/P detection rate | Percentage of screening patients with at least one SSA/P found - to be compared between Gastroenterologists and Surgeons and based on scheduling of the procedure | Day 1 | 
| Polyp detection rate | Percentage of screening patients with at least one polyp found - to be compared between Gastroenterologists and Surgeons and based on scheduling of the procedure | Day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
polyps
Risk of COVID-19 Infection After Vaccination

Study Overview
=================
Brief Summary
-----------------
The purpose of this observational nationwide study is to evaluate the effects of three different COVID-19 vaccines for the outcome of different severities of incident COVID infection.

Official Title
-----------------
Risk of COVID-19 Infection After Vaccination: A Nationwide Study Comparing BNT162b2, mRNA-1273 and ChAdOx1

Conditions
-----------------
Covid19, Vaccination; Infection

Intervention / Treatment
-----------------
* Other: The COVID-19 vaccines BNT162b2, mRNA-1273 and ChAdOx1


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Living in Sweden and vaccinated with BNT162b2, mRNA-1273 or ChAdOx1 All individuals with a previous COVID-19 infection Controls matched 1:1 to the groups above Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 0 Years
Maximum Age: 110 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: The COVID-19 vaccines BNT162b2, mRNA-1273 and ChAdOx1|The purpose of the study is to compare the effects of BNT162b2, mRNA-1273 and ChAdOx1 with respect to incident COVID-19 infection of different severities.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incident COVID-19 infection | Four different severities: Being diagnosed, hospitalized, ICU-care and death within 30 days of diagnosis | Up to six months after vaccination | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19, Vaccination, Nationwide observational study
Investigation of Genetic Risk of Atrial Fibrillation

Study Overview
=================
Brief Summary
-----------------
The atrial fibrillation (AF) is the most common cardiac rhythm disturbance that is responsible for substantial morbidity and mortality independent of associated heart disease or other risk factors. Even in the absence of preexisting cardiovascular disease, AF remains significantly associated with excess mortality rates. The current unsatisfactory treatment for AF comes from lack of understanding of the pathophysiology of AF. The purpose of this study is to identify gene polymorphisms that confer susceptibility to atrial fibrillation. Patients with AF（N=500） and healthy volunteer（N=1000） without AF are enrolled in this study. Patients with coronary artery disease, severe valvular heart disease, cardiomyopathy or heart failure were excluded from the study.

Official Title
-----------------
Investigation of Genetic Risk of Atrial Fibrillation

Conditions
-----------------
Atrial Fibrillation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of atrial fibirillation Exclusion Criteria: coronary artery disease severe valvular heart disease cardiomyopathy heart failure
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Atrial Fibrillation
Reliability of Rehabilitative Ultrasound for the Quadriceps Muscle and Sarcopenia in Poststroke Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is search the interrater and intrarater reliability of the quadriceps muscle using rehabilitative ultrasound imaging and search for an association between sarcopenia and quadriceps muscle in poststroke patients.

Detailed Description
-----------------
Poststroke patients often suffer from muscle atrophy in quadriceps muscle. Quadriceps muscle is essential for independent standing or ambulation after stroke. Quadriceps muscle consists of four different muscles: rectus femoris, vastus intermedius, vastus lateralis and medialis. The present study search for reliability for rectus femoris and vastus intermedius muscle thickness and cross-sectional area using rehabilitative ultrasound imagining. Longitudinal and transverse ultrasound imagining of the muscle thickness will be performed on both rectus femoris and vastus intermedius muscles for both extremities. The procedures will be repeated by two experts at two separate times (7-10 days). For sarcopenia measurement grip strength and DEXA measurements of the patients will be calculated. Totally 68 patients will be included in the study.

Official Title
-----------------
Reliability of Rehabilitative Ultrasound Imaging for the Quadriceps Muscle and Sarcopenia in Poststroke Patients

Conditions
-----------------
Sarcopenia, Stroke, Complication, Quadriceps Muscle Atrophy, Hemiplegia, Ultrasonography, Hand Strength

Intervention / Treatment
-----------------
* Diagnostic Test: Rehabilitative Ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Poststroke patients (>6 months) Exclusion Criteria: < 6 months after stroke Multiple stroke
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Rehabilitative Ultrasound|Ultrasound imagining|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Thickness of Rectus Femoris Muscle | Longitudinal and Transverse thickness of rectus femoris muscle | One week | 
| Thickness of vastus intermedius muscle | Longitudinal and Transverse thickness of vastus intermedius muscle | One week | 
| Cross-sectional area of Rectus Femoris Muscle | Cross-sectional area of Rectus Femoris Muscle | One week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sarcopenia, Stroke, Quadriceps Muscle Atrophy, Hemiplegia, Ultrasonography, Hand Strength
Mechanisms of Human Cutaneous Microcirculation in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
Microvascular dysfunctions are critical events in several diseases including diabetes. This study will develop a methodology for microvascular investigation in human skin. The purpose of the study is to investigate the physiological response of the cutaneous microcirculation to physical, thermal, mechanical or chemical stimulations.

Detailed Description
-----------------
This study has investigated various aspects of the physiology of the microcirculation in the past years and is still recruiting under parallel protocols of physiological investigations of the neurovascular control of the cutaneous microcirculation.

Official Title
-----------------
Etude de la Reserve Vasomotrice Microcirculatoire cutanée

Conditions
-----------------
Healthy Volunteers

Intervention / Treatment
-----------------
* Device: pressure strain system, iontophoresis
* Drug: scopolamin
* Drug: emla
* Drug: capsaicin
* Drug: aspirin
* Drug: clopidogrel
* Drug: celecoxib
* Drug: indomethacin
* Drug: acetylcholine
* Drug: sodium nitroprusside
* Drug: brethyllium
* Device: general and local heating


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy volunteers with no clinical signs of, or risk factors for, vascular disease Exclusion Criteria: Smokers, Pregnancy, Allergy,

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: pressure strain system, iontophoresis|nan|
|Drug: scopolamin|nan|
|Drug: emla|nan|
|Drug: capsaicin|nan|
|Drug: aspirin|nan|
|Drug: clopidogrel|nan|
|Drug: celecoxib|nan|
|Drug: indomethacin|nan|
|Drug: acetylcholine|nan|
|Drug: sodium nitroprusside|nan|
|Drug: brethyllium|nan|
|Device: general and local heating|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Amplitude of the vasomotor response to stimuli |  | 1 hour | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Kinetics of the vasomotor response to stimuli |  | 1 hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Physiology, Microcirculation, Laser-Doppler Flowmetry
Breast Cancer and Chemo-amennorhea

Study Overview
=================
Brief Summary
-----------------
Relation between chemotherapy and amennorhea

Official Title
-----------------
Etude Prospective Multicentrique de l'aménorrhée Chimio-induite et de sa réversibilité Dans le Cancer du Sein Chez Des Patientes préménopausées Recevant Une chimiothérapie Adjuvante ou néoadjuvante. Etude Améno-Chimio.

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Other: observational


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pre-menauposal breast cancer needed to be treat with chemotherapy - Exclusion Criteria: metastases menopausal -
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| FEC- TC<br>Fluorouracil- Epiadriamycine- Cyclophosphamide Taxotère-Cyclophosphamide | Other: observational<br>* standard of care fore patients with non metastatic breast cancer<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence and duration of the amenorrhea induced by chemotherapy |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pre-menauposal, neo-adjuvant or adjuvant chemotherapy, no metastases
Access Creation for Hemodialysis: Association With Structural Changes of the Heart

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if the creation of a fistula or a graft plays a role in the development of heart disease for patients undergoing hemodialysis

Detailed Description
-----------------
Patients with end stage renal disease are at 18-20 times greater risk of dying from cardiovascular disease as the general population. Both traditional and non-traditional cardiovascular risk factors are thought to be important. Of the non-tradtional cardiovascular risk factors, creation of an arteriovenous fistula or graft for the purposes of a blood access for hemodialysis may contribute to an elevation in BNP and left ventricular hypertrophy - both factors that have been associated with an increased risk of mortality Prior to access creation and at one month and one year post access creation - samples for BNP will be collected Prior to access creation and at one year post access creation - echocardiography will be performed

Official Title
-----------------
Access Creation for Hemodialysis: Potential Contribution to Left Ventricular Remodelling

Conditions
-----------------
Arteriovenous Fistula, Arteriovenous Graft, Left Ventricular Hypertrophy, Brain Natriuretic Peptide

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1)Hemodialysis 2)high risk for heart failure (DM, age&gt;50, and/or systolic dysfunction) 3) first arteriovenous fistula/graft 4) informed consent 5) technically adequate echocardiogram 6) stable hgb(&gt;100) 7) stable mineral metabolism (normal calcium, phosphate &lt;2.1mmol/L, PTH&gt;50pmol/L) Exclusion Criteria: 1)Expected survival &lt;1 year 2) Expected to get a living donor transplant in one year 3)primary access failure 4) ARF

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hemodialysis, Arteriovenous Fistula, Arteriovenous Graft, Left Ventricular Hypertrophy, Brain Natriuretic Peptide